An underactive urinary bladder (UUB), often occurring after surgery, can lead to urinary retention even in otherwise healthy people. We systematically reviewed published reports to determine whether the use of parasympathomimetic agents is warranted in patients with a UUB. Agents allegedly useful in treating UUB were identified from urology and pharmacology textbooks. A systematic search for randomized clinical trials in patients with UUB using these agents revealed 10 such studies. Controls typically received placebo or no treatment. While three studies reported statistically significant improvements relative to the control group, six did not and one even reported a significant worsening of symptoms. There was no evidence for differences between individual drugs, specific uses of such drugs, or in outcome measures. We conclude that the available studies do not support the use of parasympathomimetics for treating UUB, specifically when frequent and/or serious possible side-effects are taken into account.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410X.2006.06742.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of photobiomodulation and bethanechol chloride treatment on salivary composition and flow rate in head and neck cancer patients undergoing radiotherapy: longitudinal interventional experimental clinical study.
Support Care Cancer
January 2025
Department of Stomatology, Federal University of Paraná, Av. Prefeito Lothário Meissner, 632, 80210-170, Curitiba, PR, Brazil.
Objective: To evaluate the efficacy of photobiomodulation therapy (PBMT) and bethanechol chloride (BC) on the quantity and quality of saliva in patients undergoing radiotherapy (RT) for head and neck cancer.
Methods: Saliva samples were collected from patients before and after RT, who were treated with PBMT or BC. Clinical parameters, including salivary flow rate (SFR), pH, xerostomia, and concentrations of macro and microelements in saliva, were assessed.
Design, synthesis and biological evaluation of galantamine analogues for cognitive improvement in Alzheimer's disease.
Eur J Med Chem
February 2025
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Liaoning, Shenyang, 110016, China. Electronic address:
Galantamine plays a crucial role in the management of brain disorders. In this study, a series of galantamine analogues were designed, synthesized and evaluated as potential therapeutic agents for Alzheimer's disease (AD). Compound C2, a dual inhibitor of cholinesterase, was obtained by introducing a benzylpyridine ring to the hydroxyl group of galantamine.
View Article and Find Full Text PDFXanomeline/Trospium Chloride: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Xanomeline/trospium chloride (COBENFY™), formerly KarXT, is a first-in-class, oral, fixed-dose muscarinic agonist/antagonist combination being developed for use in schizophrenia and Alzheimer's disease psychosis. Xanomeline is thought to confer efficacy by acting as an agonist at M and M muscarinic acetylcholine receptors in the brain, and trospium chloride reduces the peripheral cholinergic adverse events associated with xanomeline. Xanomeline/trospium chloride received its first approval on 26 September 2024 in the USA for the treatment of schizophrenia in adults.
View Article and Find Full Text PDFInnovative bioinspired hydrogel scaffolds enabling in-situ hybrid nanoflower integration for dual-mode acetylcholinesterase inhibitor profiling.
Biosens Bioelectron
March 2025
College of Chemistry and Chemical Engineering, China University of Petroleum (East China), Qingdao, 266580, PR China. Electronic address:
This study introduces an innovative bioinspired hydrogel scaffold tailored to facilitate the in-situ integration of hybrid nanoflowers (HNFs) into the sensing interface, thereby establishing a versatile dual-mode platform for the sensitive profiling of acetylcholinesterase (AChE) inhibitors, a pivotal aspect in the pursuit of Alzheimer's disease therapeutics. Mimicking the tenacious anchoring of natural tree roots, our design employs magnetic bead imprinting with Strep-Tactin-coated magnetic beads (STMBs) to shape the hydrogel, which is then complemented by the integration of AChE-specific aptamers. This configuration creates a stable and biomimetic environment that nurtures HNF growth, thereby enhancing the binding integrity of HNFs with sensing interfaces.
View Article and Find Full Text PDFEfficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis.
J Psychiatr Res
January 2025
Department of Cardiology Research, Dante Pazzanese Institute of Cardiology, São Paulo, São Paulo, Brazil.
Article Synopsis
- Schizophrenia is a severe mental illness with high mortality rates, and Xanomeline combined with Trospium has shown promise in clinical trials as a treatment option.
- A meta-analysis of 3 randomized controlled trials involving 674 patients revealed that XTC significantly improved schizophrenia symptoms measured by the PANSS total score, although it also led to nausea and other cholinergic side effects.
- While XTC effectively reduces symptoms of schizophrenia, the associated adverse effects may affect patient compliance and overall treatment tolerability.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!